GenomeWeb recently reported that Curewize Health in Yokneam aims to have a test for guiding treatment decisions in acute lymphoblastic leukemia patients on the European market by the beginning of next year. Curewize claims that the clinical test trial that it completed on patients from a European National Registry Study provides information related to the possibility of relapse in patients based on the presence or absence of microRNA biomarkers. The test stratifies the patients into risk-based treatment groups. , identifying patients that are at a high risk of relapse before starting treatment.